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ABSTRACT
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare subtype of 
leukemia/lymphoma, whose diagnosis can be difficult to achieve due to its clinical and 
biological heterogeneity, as well as its overlapping features with other hematologic 
malignancies. In this study we investigated whether the association between the 
maturational stage of tumor cells and the clinico-biological and prognostic features of 
the disease, based on the analysis of 46 BPDCN cases classified into three maturation-
associated subgroups on immunophenotypic grounds. Our results show that blasts 
from cases with an immature plasmacytoid dendritic cell (pDC) phenotype exhibit an 
uncommon CD56− phenotype, coexisting with CD34+ non-pDC tumor cells, typically 
in the absence of extramedullary (e.g. skin) disease at presentation. Conversely, 
patients with a more mature blast cell phenotype more frequently displayed skin/
extramedullary involvement and spread into secondary lymphoid tissues. Despite the 
dismal outcome, acute lymphoblastic leukemia-type therapy (with central nervous 
system prophylaxis) and/or allogeneic stem cell transplantation appeared to be the 
only effective therapies. Overall, our findings indicate that the maturational profile 
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of pDC blasts in BPDCN is highly heterogeneous and translates into a wide clinical 
spectrum -from acute leukemia to mature lymphoma-like behavior-, which may also 
lead to variable diagnosis and treatment.
INTRODUCTION
Blastic plasmacytoid dendritic cell neoplasm 
(BPDCN) is a relatively rare subtype of leukemia/
lymphoma - < 1% of hematologic malignancies [1]- which 
has been recently categorized in the 2008 World Health 
Organization (WHO) classification of hematological 
diseases [2] under acute myeloid leukemia (AML) and 
related precursor neoplasms. Accumulating evidences 
show that the normal cellular counterpart of BPDCN 
resides in the plasmacytoid dendritic cell (pDC) lineage 
[3]. Despite all the above, diagnosis of BPDCN still 
remains a challenge; this is probably due to several 
reasons including its overlapping features with other 
entities, the lack of recurrent and specific chromosomal 
abnormalities [4, 5], and its heterogeneous clinical 
presentation with multiple and variable tissue localizations 
[6–8]. In addition, diagnosis of BPDCN can be difficult to 
achieve, particularly when blast cells do not completely 
fit the typical CD4+ CD56+ HLA-DRhi CD123+ lineage 
(Lin)− immunophenotypic profile [6, 9]. In fact, at present 
it is now well-established that tumor cells from BPDCN 
do express markers which have been classically related to 
other cell lineages such as CD33, TdT, CD79a, CD2 and 
CD7 [10, 11], and evidences exist about a broad range 
of atypical phenotypic profiles in a substantial proportion 
of cases (up to more than one third of cases), including 
absence of CD56 [12] and CD4 [13]. Such heterogeneity 
is also observed at the genetic and molecular level, since 
multiple and diverse, but unspecific, chromosomal and 
molecular alterations have been identified [4, 5] with 
even mutually exclusive gene mutations [14]. Therefore, 
BPDCN are not only clinically heterogeneous but they 
also show a considerable biologic diversity which in 
some cases makes diagnosis difficult. This, together 
with the low prevalence of the disease, has hampered 
the study of large series of patients, with few exceptions 
[6, 7, 15], most reports on BPDCN being based on single 
or just a few cases. Besides, some of the few larger series 
reported so far are biased, as they generally include only 
cases showing cutaneous involvement in the absence 
of systemic disease and/or they have used rather (even 
retrospective) restrictive phenotypic inclusion criteria; this 
has probably contributed to the lack of awareness about 
disease heterogeneity. In such case we might wonder 
whether or not, the clinical, phenotypical and genetic 
diversity of BPDCN (e.g. the maturational stage of blast 
cells and/or their genetic profile) could contribute to 
further subclassify this entity, similarly to what happens 
with other neoplasms, such as B and T-cell malignancies 
or even AML [16].
Here we describe a relatively large series of 
46 BPDCN classified into three subgroups, based on the 
expression of maturation-associated immunophenotypic 
markers on tumor vs. normal pDC and pDC precursors. 
Our major goal was to investigate whether the stage 
of maturational arrest of pDC tumor cells would be 
associated with distinct and unique clinico-biological and 
prognostic features of the disease.
RESULTS
Clinical and laboratory features at presentation
From all 46 cases analyzed, four (9%) were 
children (median age of 11 years; range: 8 to 12 years) 
and 42 were adults (median age of 71 years; range: 25 to 
91 years), with a clear male predominance: 35 males 
(76%) vs. 11 females (24%) (Table 1). Most cases (27/45, 
60%) consulted because of organ involvement (e.g. skin 
lesions) in association with B symptoms (32/45 cases, 
71%) (Table 1). In a smaller proportion of cases, diagnosis 
was made because of bleeding (6/45, 13%), bone pain 
(4/45, 9%) or just the presence of cytopenias with or 
without blast cells in a routine blood analysis (5/44, 11%). 
In line with this, most cases presented with extramedullary 
involvement (33/45, 73%) mainly consisting of skin 
lesions (29/45 cases, 64%) and/or, to a lesser extent, testis 
(6%) and central nervous system (CNS) involvement 
(9% of cases). Presence of lymphadenopathies, 
splenomegaly and hepatomegaly was detected on physical 
examination in 51%, 38% and 22% of cases, respectively. 
Five patients (16%) had an associated myelodysplastic 
syndrome (MDS) and 3 (7%) had other non-hematological 
neoplasms (prostate −n = 2- and colon cancer).
Blood cell counts revealed leukocytosis (> 10 × 109 
WBC/l) in 33% of the cases, anemia (< 100g hemoglobin/l) 
in 63%, thrombocytopenia (< 100 × 109/l) in 64% of the 
cases and neutropenia (< 1.5 × 109/l) in around half (48%) 
of cases (Table 2). LDH serum levels were increased in 
55% of the patients. The majority of cases (61% and 93%) 
showed presence of blast cells in both PB (median blast 
cell percentage of 39%; range: 2% to 83%) and BM 
(median of 78%; range: 4% to 100%), respectively.
Immunophenotypic subgroups of blastic 
plasmacytoid dendritic cell neoplasms
Patients with BPDCN were divided into three 
groups according to the maturational stage of the blast/
tumor cells as defined by the pattern of expression of 
CD34 and CD117: 1) immature blastic pDC neoplasms 
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(8/46 cases; 17%) showed expression of CD34 in at least 
a fraction of the blast cells; 2) intermediate blastic pDC 
neoplasms (24/46 patients; 52%) typically displayed partial 
positivity for CD117 in the absence of CD34 expression 
on the blast cells, and; 3) mature cases (14/46 cases; 30%) 
had a CD34− CD117− tumor pDC immunophenotype. 
Of note, among all immature cases (Group 1) neoplastic 
pDC systematically coexisted with another blast cell 
population of myeloid or mixed myeloid plus B-lymphoid 
origin, accounting for a median of 50% of the whole blast 
cell population (range: 30% to 90%); such coexisting 
non-pDC lineage blast cells systematically showed 
strong CD34 and CD117 expression, whereas the pDC 
component was typically partially positive for CD34 and 
negative or dim positive for CD117 (Figure 1J, 1K, and 
1L). In contrast, both intermediate (Group 2) and mature 
(Group 3) blastic pDC neoplasms showed no blast/tumor 
cell population other than the pDC, all these cases being 
systematically negative for CD34 by definition. Expression 
of CD117 (in the absence of CD34) was restricted per 
definition to Group 2, with a median percentage of CD117+ 
cells of 18% (range: 5% to 100%).
Other immunophenotypic markers which 
showed different patterns of expression on pDC blast 
Table 1: Clinical characteristics of blastic plasmacytoid dendritic cell neoplasms patients classified 
according to their maturation-associated immunophenotypic profile
Blast cell phenotype
Demographics
Total cases Group 1 (immature)
Group 2 
(intermediate)
Group 3 
(mature) P-value
n = 46 n = 8 n = 24 n = 14
Age (years)* 61 ± 22 (8–91) 68 ± 22 (25–91) 56 ± 23 (8–85) 68 ± 19 (11–83) .05c
Children/Adults 4/42 (9%/91%) 0/8 (0%/100%) 3/21 (13%/87%) 1/13 (7%/93%) NS
Sex (male/female) 35/11 (76%/24%) 6/2 (75%/25%) 15/9 (63%/37%) 14/0 (100%/0%) .008c
Reason for consulting
Routine blood analysis 5/44 (11%) 0/6 (0%) 3/24 (13%) 2/14 (14%) NS
B & other general symptoms 32/45 (71%) 6/7 (86%) 17/24 (71%) 9/14 (64%) NS
Bleeding 6/45 (13%) 1/7 (14%) 3/24 (13%) 2/14 (14%) NS
Bone pain 4/45 (9%) 0/7 (0%) 4/24 (17%) 0/14 (0%) NS
Organ involvement 27/45 (60%) 0/7 (0%) 14/24 (58%) 13/14 (93%) ≤ .03a, b, c
Physical examination
Adenopathies 23/45 (51%) 0/7 (0%) 14/24 (58%) 9/14 (64%) .007a, b
Splenomegaly 17/45 (38%) 0/7 (0%) 13/24 (54%) 4/14 (29%) .01a
Hepatomegaly 10/45 (22%) 0/7 (0%) 7/24 (29%) 3/14 (21%) NS
Extramedullary involvement 33/45 (73%) 1/7 (14%) 19/24 (79%) 13/14 (93%) ≤ .004a, b
   - Skin1 29/45 (64%) 1/7 (14%) 16/24 (67%) 12/14 (86%) ≤ .02a, b
   - CNS 4/45 (9%) 0/7 (0%) 3/24 (13%) 1/14 (7%) NS
   - Testis2 2/34 (6%) 0/5 (0%) 1/15 (7%) 1/14 (7%) NS
Clinical history
Associated neoplasia 3/44 (7%) 0/6 (0%) 1/24 (4%) 2/14 (14%) NS
Myelodysplastic syndrome 5/32 (16%) 2/6 (33%) 1/19 (5%) 2/7 (29%) NS
Results expressed as number of cases from all cases with available data and (percentage) or as *mean ± one standard 
deviation (range). Statistically significantly differences were found between agroup 1 group 2, bgroup 1 group 3 and 
cgroup 2 group 3. 1None showed mucosal involvement, 2only in male patients, both children. NS: no statistically 
significant differences (p > 0.05), CNS: central nervous system.
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cells included (Supplementary Table 2 and Figure 2): 
CD7 and CD33 which showed a greater expression 
among cases in the intermediate immunophenotypic 
Group 2 (p = .008 and p = .04, respectively) and to a 
lesser extent also, in case of CD7, in Group 3 (p > .05); 
CD56, which was dimly expressed only in a fraction of 
cases in Group 1, but widely and intensely positive on 
tumor cells from Group 2 and Group 3 cases (p ≤ .04), 
and; NG2, a marker that was absent in Group 1 cases 
(p ≤ .03) but clearly expressed in most of the other more 
mature Group 2 and Group 3 patients (Figure 1, panel II, 
plots M to X and Figure 2).
Clinical and laboratory features of the distinct 
maturation-associated subgroups of BPDCN
Overall, no significant differences were observed 
among the three phenotypic groups of BPDCN, as regards 
the distribution of patients according to age. Although a 
clear male predominance was found in all groups, this 
was significantly more pronounced in Group 3, where 
all 14 cases were males (p < .008) (Table 1). Patients in 
the three groups showed a similar reason for consulting 
except for cases in Group 1 which less frequently referred 
because of organ involvement. In line with this, Group 1 
cases also showed a significantly lower frequency (vs. the 
other two groups) of extramedullary involvement (14% vs. 
79% and 93%, p ≤ .004), lymphadenopathies (0% vs. 58% 
and 64%, p ≤ .007) and splenomegaly (0% vs. 54% and 
29%, p = .01). Group 2 cases showed intermediate profiles 
between those of Group 1 and Group 3 patients, as regards 
the frequency of extramedullary involvement, particularly 
of skin lesions.
Despite similar levels of BM and PB infiltration 
by tumor pDCs were found among the three groups, 
the frequency of anemia, leukopenia and neutropenia 
progressively decreased from Group 1 to Group 2 and 
Group 3 cases (Table 2). In contrast, the frequency of 
thrombocytopenia was slightly higher among the latter two 
groups. The frequency of cases with increased LDH levels 
was significantly higher in Group 3 vs. Group 1 cases.
Patient treatment and outcome
All 4 Group 1 patients who were treated with 
curative intention, systematically received an AML-type 
regimen; this is in contrast with Group 3 cases, who 
more frequently received either lymphoma (6/9 cases) 
or acute lymphoblastic leukemia (ALL; 3/9 patients) 
directed therapies (p = .01) (Table 3). In turn, Group 2 
patients received AML (8/19), ALL (5/19) and lymphoma 
(6/19) associated therapy. Despite the diverse therapies 
administered, complete remission (CR) was achieved 
in the great majority of cases (92%) who completed 
Table 2: Blastic plasmacytoid dendritic cell neoplasms classified according to their maturation-
associated immunophenotypic profile: laboratory parameters
Blast cell phenotype
Laboratory parameters
Total cases Group 1 (immature)
Group 2 
(intermediate)
Group 3 
(mature) P-value
n = 46 n = 8 n = 24 n = 14
Anemia (< 100 g/l) 28/44 (64%) 6/7 (86%) 16/24 (67%) 6/13 (46%) NS
Leukopenia (< 4 × 109/l) 13/43 (30%) 4/7 (57%) 8/23 (35%) 1/13 (8%) .03a
Neutropenia (< 1.5 × 109/l) 20/41 (49%) 6/7 (86%) 12/22 (55%) 2/12 (17%) ≤ .04a, b
Thrombocytopenia (< 100 × 109/l) 28/43 (65%) 3/7 (43%) 16/24 (65%) 9/12 (75%) NS
Leukocytosis (> 10 × 109/l) 14/43 (33%) 0/7 (0%) 6/23 (26%) 8/13 (62%) ≤ .04a, b
Elevated LDH (≥ 450 U/l) 22/40 (55%) 1/6 (17%) 11/21 (52%) 10/13 (77%) .02a
Presence of blast cells (by morphology)
Peripheral blood % cases 27/44 (61%) 4/7 (57%) 14/24 (58%) 9/13 (69%) NS
% blast cells1* 39% (2%–83%) 11% (2%–35%) 45% (2%–80%) 39% (10%–83%) NS
Bone marrow % cases 41/44 (93%) 8/8 (100%) 21/24 (88%) 12/12 (100%) NS
% blast cells1* 78% (4%–100%) 68% (46%–73%) 80% (18%–99%) 85% (4%–100%) NS
Results expressed as number of cases from all cases with available data (percentage) or as *median (range). 
Statistically significantly differences were found between agroup 1 group 3 and bgroup 2 group 3. 1Only in cases 
with blast cells. NS: no statistically significant differences (p > 0.05) found, LDH: lactate dehydrogenase; β2-microg: 
β2-microglobulin. No statistical differences were observed among the groups regarding creatinine and C-reactive 
protein levels.
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the treatment protocol (n = 25), regardless of their 
phenotypic group (p > .05); nevertheless, the outcome 
was poor with a median overall survival (OS) of only 
11 months due to early relapse. Interestingly, relapse and/
or progression at the CNS level was observed in a high 
proportion of cases (33%), mostly among Group 2 and 
Group 3 (29% and 50%, respectively) patients (Table 3); 
this was even more frequent when only patients who 
achieved CR were evaluated (60%), particularly in those 
cases where a lymphoma-type therapy was administered 
(Supplementary Table 3). Overall, no significant 
differences were observed in the outcome of the patients 
from the three distinct immunophenotypic groups (Table 3 
and Figure 3A and 3B). In contrast, adulthood (age at 
diagnosis > 15 years; p = .04) (Figure 3C), presence of 
lymphadenopathies (p = .03) and hepatomegaly (p = .03) 
Figure 1: Illustrating dot plots of the three immunophenotypically defined groups of BPDCN. The neoplastic plasmacytoid 
dendritic cell population is depicted as black dots, whereas other leukocytes are depicted in gray. Panel I: plots A to I illustrate a combination 
of markers which are useful for the identification of blastic pDC, while plots J to L show the pattern of expression of CD34 and CD117 
for representative cases from the different maturation-associated groups of BPDC neoplasms here defined. Panel II: plots M to X display 
the pattern of expression observed for those markers found to be expressed at statistically different levels among the three maturation-
associated groups of BPDC neoplasms.
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(Figure 3D and 3E), skin lesions (p = .04) (Figure 3F), 
increased serum LDH (≥ 450U/l; p = .001) (Figure 3H) and 
β2-microglobulin (≥ 3 mg/l; p = .02) were all associated 
with a poorer outcome (Table 4). In turn, leukopenia 
(p = .05) (Figure 3G), administration of ALL-type therapy 
(Figure 3I) and allogeneic stem cell transplantation 
(Figure 3J) (p = .03 and p = .04, respectively) were 
associated with a better outcome. Multivariate analysis 
of prognostic factors (Table 4) showed that serum LDH 
levels were the only independent prognostic factor for OS 
in aggressively-treated patients (p = .005, HR = 6.6; 95% 
CI = 1.8–24.8).
DISCUSSION
BPDCN is a rare but very aggressive disease whose 
nomenclature, ontogeny and underlying biology have 
evolved over the years, since its first description by Brody 
et al. in 1995 [17]. Despite the number of cases reported in 
recent years has increased, as well as our knowledge about 
the biology of its postulated normal cellular counterpart 
(i.e. pDC lineage cells) [9, 18–20], the diagnosis of the 
disease still remains a challenge. This is due in part, to 
the clinical and phenotypical diversity observed among 
the patients and the overlapping features with other 
hematologic malignancies. In order to elucidate whether 
the clinical heterogeneity of BPDCN is related to the 
maturation stage of pDC tumor cells, here we analyzed a 
relatively large series of 46 patients, whose general clinical 
features were fully compatible with those previously 
reported for this rare entity [6, 7], except for the proportion 
of cases presenting with skin involvement that was lower 
(64% vs. 76%–100%) in our vs. other series [6, 7, 15, 21]. 
Although there is no definitive explanation for such 
difference, it might be due to the fact that until recently, 
skin lesions have been considered one of the major features 
Figure 2: Immunophenotypic differences observed for individual markers on neoplastic pDC from PBDCN patients 
classified into the three different maturation-associated groups defined in this study. Only those markers that showed 
statistically significant differences -CD7, CD33, CD34, CD56, CD117 and NG2- among the three maturation-associated groups of BPDC 
neoplasms are shown; the percentage of positive cases and the pattern of expression (intensity) observed for the above listed markers 
are represented as bars for each group of patients. The correspondence between MFI values and the different categories of intensity of 
expression defined for the individual markers is shown in Supplementary Table 2. Statistically significant differences were found between 
*Group 1 vs. Group 2, #Group 1 vs. Group 3 and ♦Group 2 vs. Group 3.
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that point to the diagnosis of BPDCN and consequently, 
a fraction of BPDCN patients, who have no cutaneous 
manifestations, might have gone undetected/not identified. 
Alternatively, a bias in sample selection could also exist, as 
more blood and BM vs. tissue samples from complex cases 
are referred from other centers to our institution.
Once we grouped our cases according to the 
immunophenotypic maturation profile of pDC-lineage 
tumor cells, important differences were noted between 
the immature and the more mature cases, the intermediate 
group showing also intermediate features. Despite CD34 
has been frequently considered as an exclusion marker 
for the diagnosis of BPDCN [11, 22], this marker was 
expressed in a fraction of pDC-lineage commited blast 
cells in around one fifth of our cases. Interestingly, these 
CD34+ BPDCN cases systematically had a second CD34+ 
blast cell population with a minimally differentiated (non-
lymphoid) phenotype. These results support and extend 
on previous observations by the Hellenic Dendritic Cell 
Leukemia Study Group, which found similar phenotypic 
and clinical characteristics to those of our Group 1 cases 
in 4/26 (15%) of their BPDCN patients [6]. If the WHO 
2008 criteria [2] would be strictly applied, these cases 
would be classified as acute leukemia of ambiguous or 
minimally differentiated myeloid lineage, because of 
the lack of clear differentiation markers for cell lineages 
other than pDC. Of note, lymphoid lineage-committed 
blast cells have also been reported in a smaller proportion 
of these CD34+ cases ([6] and personal unpublished 
observations). Previous studies have shown that among 
CD34+ pDC cases, both the pDC lineage-committed 
and the minimally differentiated blast cell population 
coexisting in individual patients, share the same 
chromosomal aberrations [23, 24], which suggests that 
both cell populations arise from a common ancestral 
leukemia cell, and that the pDC-lineage component may 
represent the more differentiated blast cell compartment. 
Of note, in these CD34+ cases, the pDC-lineage committed 
Table 3: Type of therapy and clinical outcome of patients with BPDCN classified according to the 
immunophenotypic-associated maturation profile of blast cells
Blast cell phenotype
Type of therapy administered
Total cases Group 1 (immature)
Group 2 
(intermediate)
Group 3 
(mature) P- value
n = 46 n = 8 n = 24 n = 14
AML-type 12/45 (27%) 4/8 (50%) 8/23 (35%) 0/14 (0%) ≤. 01a, b
High risk ALL-type 8/45 (18%) 0/8 (0%) 5/23 (22%) 3/14 (21%) NS
C(H)OP and C(H)OP-like type 12/45 (27%) 0/8 (0%) 6/23 (26%) 6/14 (43%) .04a
AHSC transplantation 5/45 (11%) 1/8 (13%) 4/23 (17%) 0/14 (0%) NS
Palliative 10/45 (22%) 3/8 (38%) 3/23 (13%) 4/14 (29%) NS
No treatment 3/45 (7%) 1/8 (13%) 1/23 (4%) 1/14 (7%) NS
Clinical outcome
Median OS (months) 7 (4–10) 2 (0–4) 10 (5–15) 4 (0–10) NS
Complete remission1 23/25 (92%) 2/2 (100%) 14/15 (93%) 7/8 (88%) NS
Relapse 17/23 (74%) 1/2 (50%) 10/14 (71%) 6/7 (86%) NS
CNS relapse/progression 10/30 (33%) 0/3 (0%) 5/17 (29%) 5/10 (50%) NS
Median OS of aggressively treated 
non-transplanted cases (months) 11 (5–17) 23
2 11 (7–15) 10 (0–23) NS
Overall mortality 42/46 (91%) 7/8 (88%) 22/24 (92%) 13/14 (93%) NS
Early deaths 12/46 (26%) 4/8 (50%) 4/24 (17%) 4/14 (29%) NS
Deaths after remission 18/23 (78%) 1/2 (50%) 11/14 (79%) 6/7 (86%) NS
Results expressed as number of cases from all cases with available data (percentage). Statistically significantly differences 
were found between agroup 1 group 3 and bgroup 2 versus group 3. 1Only in aggressively treated patients, 2only one case. 
BPDC: blastic plasmacytoid dendritic cell; AML: acute myeloblastic leukemia; ALL: acute lymphoblastic leukemia; NS: no 
statistically significant differences (p > 0.05); AHSC: allogeneic hematopoietic stem cell; OS: overall survival; CNS: central 
nervous system.
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blast cell population frequently did not show aberrant 
expression of either CD56 or NG2 [6, 23], in contrast to 
most other more mature (Group 2 and Group 3) BPDCN 
cases. Furthermore, this subset of CD34+ BPDCN cases 
also showed a unique clinical behavior vs. the other cases; 
e.g. at presentation they typically lacked skin lesions and 
extramedullary disease. These results indicate that in 
these patients blast cells appear to be almost exclusively 
confined to the BM with some spreading to PB, reflecting 
a typical “acute leukemia-like” behavior, associated in 
most cases with multiple cytopenias. This is in line with 
the immunophenotypic profile of blast cells from cases 
classified as immature (Group 1) BPDCN, supporting 
the notion that they would mimic a stem cell malignancy 
whose blast cells would have limited ability to differentiate 
into the early stages of pDC lineage. Conversely, patients 
classified under Group 3, displayed a more mature pDC 
immunophenotype, associated with a greater frequency of 
extramedullar involvement (particularly in the skin) and 
spread into the lymph nodes and other secondary lymphoid 
tissues; such clinical behavior mimics that of aggressive 
lymphomas. Altogether, these results point out to a more 
mature and differentiated tumor pDC, blocked at a stage 
where the pDC precursor already leaves the BM via PB, 
with a greater migration capacity into peripheral tissues 
and secondary lymphoid tissues, which translates into 
frequent extramedullary organ involvement. In line with 
this hypothesis, Group 2 cases showed an intermediate 
phenotypic and clinical behavior between the other two 
groups (immature and mature) of BPDCN patients. These 
results support the notion that BPDCN originates from a 
BM cell precursor that secondarily involves the skin [25] 
and other peripheral tissues and lymphoid organs, at least 
in the great majority of cases.
Figure 3: Overall survival of patients with BPDCN. Stratified according to the three pDC maturation-associated groups of 
patients. Panels A and B, age at diagnosis panel C, presence of lymphadenopathies panel D, hepatomegaly panel E, skin lesions panel F, 
leukopenia panel G, lactate dehydrogenase (LDH) serum levels panel H, type of systemic therapy administered –acute lymphoid leukemia 
(ALL)-type vs. acute myeloid leukemia (AML) or lymphoma (NHL)-type therapies- panel I, including allogeneic hematopoietic stem 
cell transplantation (AHSCT) panel J. For all panels but panel A, only those patients who had been treated with an intention to cure, are 
represented.
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Despite the here defined maturation-associated 
subgroups of BPDCN displayed a clearly different 
clinical behavior at presentation, no significant differences 
were observed among them as regards disease outcome, 
with systematically low (i.e. less than a year) OS rates. 
However, it should be noted that different treatments 
were given to these patients due to their heterogeneous 
clinical presentation and equivocal tumor cell features 
at presentation. Of note, high CR rates were obtained, 
regardless of the type of therapy administered. However, 
most cases showed an aggressive clinical course with 
early recurrence of the disease, resistance to therapy and a 
dismal prognosis with median overall survival rates of less 
than a year, fully in line with previous observations [25]. 
Despite the above, more detailed analysis of patient 
outcome according to therapy showed that cases treated 
with ALL-type protocols had a better outcome than the 
other patients, particularly than those who received 
lymphoma-type regimens (Supplementary Table 3); 
these results are also in line with previous observations 
[6, 21], although younger patients (e.g. children) were 
mostly included in the group treated with ALL-like 
protocols. Therefore, the question remains about whether 
the treatment itself or age at diagnosis, would explain the 
apparently better prognosis of this subgroup of BPDCN 
patients. In this regard, it should also be emphasized that 
the only two adults who survived so far, were both treated 
with an allogeneic stem cell transplant following ALL-
type therapy in one case and AML-type chemotherapy 
in the other patient. Despite the low number of cases 
included in each group, our results would reinforce 
previous observations suggesting a better outcome for 
patients treated with ALL-type and/or allogeneic stem cell 
transplantation [6, 7, 21, 26].
Although the potential impact of age cannot be 
ruled out, we may speculate that the better outcome of 
cases treated with ALL-type chemotherapy could be 
due to systematic administration of CNS prophylaxis, 
Table 4: Prognostic factors (univariate and multivariate analysis) for overall survival among 
aggressively-treated patients with blastic plasmacytoid dendritic cell neoplasms (n = 25)
Patient features % of 
cases
Median 
(months)
Uni P-value Multi 
P-value
Hazard 
Ratio
95% CI
Age
≤ 15 y 16 NR
.04
> 15 y 84 14
Adenopathies
No 52 22
.03
Yes 48 10
Hepatomegaly
No 72 17
.03
Yes 28 11
Skin involvement
No 44 23
.04
Yes 56 11
Leukopenia (< 4 × 109/l)
No 74 11
.05
Yes 26 23
Elevated LDH (≥ 450U/l)
No 36 23
.001 .005 6.6 1.8 – 24.8
Yes 64 10
Increased β2-M (≥ 3 mg/l)
No 43 42
.02
Yes 57 10
ALL-type treatment
No 28 10
.03
Yes 72 NR
AHSC transplantation
No 80 11
.04
Yes 20 NR
Relapse
No 32 NR
.02
Yes 68 14
Uni: univariate analysis, Multi: multivariate analysis, CI: confidence interval, NR: not reached, LDH: lactate 
dehydrogenase, β2-M: β2-microglobulin, ALL: acute lymphoblastic leukemia, AHSC: allogeneic hematopoietic stem cell.
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since a high percentage of the cases (60%) showed 
CNS involvement at relapse, particularly among non-
ALL-type chemotherapy treated patients (all but one, 
who received an ALL-type protocol). Despite the broad 
variety of prognostic factors -including therapy- found 
to be associated with patient outcome, LDH emerged as 
the only independent prognostic factor for aggressively-
treated patients, in line with the strong predictive value 
of LDH in other hematological malignancies, particularly 
mature/peripheral lymphoid tumors [27, 28].
In summary, here we show that tumor cells from 
BPDCN may show a highly variable maturational profile, 
which translates into a heterogeneous clinical behavior 
ranging from that of acute leukemia to peripheral/mature 
lymphomas, such wide clinical spectrum potentially 
leading also to variable differential diagnoses and 
administration of distinct treatment modalities. Despite 
the dismal prognosis of the great majority of patients, 
usage of ALL-type therapy with CNS prophylaxis and/
or allogeneic stem cell transplantation appears to be, 
among all regimens administered, the only effective ones. 
Overall, these results support the unique clinical and 
prognostic behavior of this subgroup of non-lymphoid 
neoplasms, which requires redefined diagnostic criteria 
and improved/novel [29] treatment strategies/regimens 
(e.g. CNS prophylaxis and consolidation regimens) for 
prolonged CR and survival rates.
MATERIALS AND METHODS
Patients and samples
A total of 46 patients (4 children and 42 adults; 
35 males and 11 females) diagnosed with BPDCN 
(according to WHO 2008 criteria [2]) and who were 
referred to the Cytometry Service of the Cancer Research 
Centre of the University of Salamanca (Salamanca, 
Spain), were included in this study. Diagnosis was 
prospectively made, based on co-expression of HLA-DR++ 
and CD123+/++ (which strongly supports a plasmacytoid 
dendritic cell origin [11, 30]) together with CD4 positivity, 
dim expression of CD45 and intermediate forward scatter 
(FSC)/sideward scatter (SSC) values, after blast cell 
commitment to other myeloid and lymphoid cell lineages 
had been excluded by morphological, immunophenotypical 
and molecular analyses (e.g. germline TCR and IGH 
gene configurations). The vast majority of cases also 
showed expression of CD36, further supporting a BPDCN 
diagnosis in the presence of the above referred phenotype.
In every patient, bone marrow (BM), peripheral 
blood (PB) and/or fine-needle aspiration (FNA) tissue 
samples were obtained and studied at diagnosis, before 
any therapy had been administered. Clinical and laboratory 
data was retrospectively collected from the referring 
centers. At the moment of closing the study, median 
follow-up was of 7 months (range: < 1 to 104 months), 
41 patients had died and 5 remained alive. The study 
was approved by the Ethics Committee of the Cancer 
Research Center, and performed following the Declaration 
of Helsinki. Each participant gave his informed consent 
prior entering the study.
Systemic therapy was administered to 32/46 patients 
and consisted of standard AML-type (cytarabine in 
combination with idarubicin, mitoxantrone or daunorubicin), 
acute lymphoid leukemia (ALL)-type (Spanish PETHEMA 
LAL-AR/2003 protocol and hyper-CVAD) [31] or 
lymphoma-type (i.e. C(H)OP) protocols, according to local 
criteria at the referring centers. The remaining patients 
received only palliative care based on local criteria.
Flow cytometry immunophenotyping
Multiparameter flow cytometry immunophenotypic 
studies were performed on whole BM, PB and FNA 
samples obtained from lymphoid tissues and/or skin 
lesions, using multicolor [3, 4, 6–8, 11] combinations of 
a large panel of monoclonal antibodies (Supplementary 
Table 1); since 2009 these included the EuroFlow 
panels [32]. In all cases, samples were stained using 
a direct immunofluorescence technique, as described 
elsewhere [20]. For data acquisition, a FACSCalibur 
and FACSCanto II flow cytometers (Becton Dickinson 
Biosciences –BD-, San Jose, CA, USA) were used. The 
Infinicyt (Cytognos, Salamanca, Spain) software program 
was used for data analysis.
Cytomorphological and 
histopathological analyses
Cytological analysis of May-Grünwald-Giemsa 
stained PB and BM smears was performed by conventional 
microscopy. In turn, conventional histopathological 
analyses were also performed in parallel for those cases 
showing lymph node and/or skin involvement, to further 
confirm tissue infiltration by pDC blast cells.
Statistical methods
Conventional descriptive and comparative statistics – 
Mann-Whitney U non-parametric test (for continuous 
variables) and the χ2 test (for categorical variables)- were 
calculated using the PASW 19 program (IBM SPSS 
Statistics, IBM, Armonk, NY, USA). Overall survival 
curves (OS) were plotted according to the Kaplan-
Meier method and compared using the (one-sided) 
log-rank test. Multivariate Cox proportional hazard 
models (stepwise regression) were applied to explore 
the independent effect of each parameter under study 
(including immunophenotypical BPDCN subgrouping) 
on OS. Hazard ratio and 95% confidence interval were 
also estimated. P values < 0.05 were considered to be 
associated with statistical significance.
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